Cytos Biotechnology

Immunodrug candidate CAD106 for Alzheimer disease gets Swedish clearance

Published in Aging and Elder Health Week, June 19th, 2005

Cytos Biotechnology AG (CYTN) announced that its collaboration partner Novartis Pharma AG has obtained approval from the Swedish health authority to initiate a phase I clinical trial with the Immunodrug candidate CAD106, an immunotherapeutic product for the treatment of Alzheimer disease.

The achievement of this milestone will trigger an undisclosed payment to Cytos Biotechnology.

CAD106 treatment aims at the generation of antibodies against the beta-amyloid-protein that inhibit the formation of "plaques" involved in the Alzheimer disease process. CAD106 is the product of the collaborative program between Novartis and Cytos Biotechnology first...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2005-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry